Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

On June 24, 2021, Paolo Tombesi, the Chief Financial Officer of Epizyme, Inc., a Delaware corporation (the "Company"), notified the Company that he will be leaving the Company to pursue other business opportunities, effective July 16, 2021.

The Company's finance function will continue to report to Robert B. Bazemore, the Company's President and Chief Executive Officer. Matthew E. Ros, the Company's Executive Vice President, Chief Strategy and Business Officer, will serve as the Company's principal financial officer, effective July 16, 2021, a role that Mr. Ros has previously served at the Company.

Mr. Ros, 55, has served as the Company's Executive Vice President, Chief Strategy and Business Officer since September 2020, served as the Company's Chief Strategy and Business Officer from September 2018 to September 2020 and served as the Company's Chief Operating Officer from May 2016 to September 2018. Mr. Ros has also served as a member of the board of directors of Cogent Biosciences, Inc., a publicly traded biotechnology company, since July 2019.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses